Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Last trade$296.32
Day change-$1.58 (-0.53%)
Day range$295.44 – $300.00
Volume51,185
Market cap$8.83B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.83B
Price / earnings
39.21×
Price / book
6.15×
Price / sales
18.78×
EV / sales
17.8×
EV / EBITDA
35.83×
Profitability
Earnings per share
$7.60
Return on assets
14.2%
Return on equity
15.68%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.89×
Quick ratio
7.53×
Cash ratio
3.26×
Cash flow
Price / cash flow
27.25×
Price / free cash flow
28.47×
Free cash flow
$310.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KRYS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$127.34M
$119.22M
$116.36M
$107.11M
$97.8M
$96.04M
$88.18M
$91.14M
Cost of revenue
$7.56M
$6.44M
$6.32M
$6.59M
$4.26M
$7.17M
$5.03M
$4.95M
Gross profit
$119.79M
$112.79M
$110.03M
$100.51M
$93.54M
$88.88M
$83.16M
$86.19M
Selling, general and administrative
$33.75M
$39.85M
$41.01M
$41.45M
$37.58M
$35.07M
$32.65M
$31.29M
Research and development
$14.89M
$14.52M
$15.33M
$14.79M
$14.59M
$14.41M
$14.26M
$13.53M
Total operating expenses
$48.64M
$54.37M
$56.35M
$56.24M
$52.16M
$49.48M
$46.9M
$44.82M
Operating income
$71.15M
$58.42M
$53.69M
$44.27M
$41.37M
$39.4M
$36.25M
$41.38M
Interest expense
$0
$7.66M
$7.75M
$0
$0
$7.38M
$7.35M
$0
Income before taxes
$80.15M
$66.08M
$61.44M
$51.13M
$47.97M
$46.78M
$43.6M
$48.61M
Income taxes
$17.08M
$11.31M
$5.51M
-$269K
-$31.4M
$8.44M
$7.86M
$3.13M
Net income
$63.07M
$54.77M
$55.93M
$51.4M
$79.37M
$38.33M
$35.73M
$45.48M
Net income attributable to common shareholders
$63.07M
$54.77M
$55.93M
$51.4M
$79.37M
$38.33M
$35.73M
$45.48M
EBITDA
$72.62M
$59.77M
$55.21M
$45.83M
$42.78M
$40.75M
$37.66M
$42.74M
Basic earnings per share
$2.13
$1.85
$1.91
$1.77
$2.74
$1.33
$1.24
$1.58
Diluted earnings per share
$2.05
$1.79
$1.83
$1.69
$2.66
$1.29
$1.20
$1.51
Recent news
Company coverage with links to the original publishers.
Krystal Biotech reported Q3 2026 earnings of $2.05 per share, beating consensus estimates of $1.84 per share, with revenues of $127.34 million exceeding expectations by 2.16%. However, despite the earnings beat and 34.8% year-to-date stock gain, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance relative to the market.
Krystal Biotech is expected to report a 30.8% year-over-year decline in earnings per share to $1.84 for Q3 2026, despite revenues rising 27.5% to $124.65 million. With a Zacks Rank of #5 (Strong Sell) and a modest positive Earnings ESP of +1.50%, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten consensus estimates in four of the last four quarters.
Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.
Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.
Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.